Clinical phenotyping strategies in selection of tobacco smokers for future genotyping studies

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 6, 2002, Pages 1071-1078

  Domino, Edward F ^a   Ni, Lisong ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Addiction; Alleles; Carbon monoxide; Cotinine; CYP2A6; Dependency; Nicotine; P450; Phenotyping; Tobacco smoking

Indexed keywords

CARBON MONOXIDE; COTININE; NICOTINE;

ABSTINENCE; ADULT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG DEPENDENCE; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HEART RATE; HUMAN; MALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; ALGORITHMS; CARBON MONOXIDE; COTININE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NICOTINE; PHENOTYPE; QUESTIONNAIRES; SMOKING; TOBACCO USE CESSATION; TOBACCO USE DISORDER;

EID: 0036801325     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00224-5     Document Type: Article

References (40)

1. Benowitz N.L., Hall S.M., Herning R.I., Jacob P., Jones R.T., Osman A.L. Smokers of low-yield cigarettes do not consume less nicotine. N. Engl. J. Med. 309(3):1983;139-142.
2. Benowitz N.L., Jacob P. III, Fong I., Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268:1994;296-303.
3. Cashman J.R., Park S.B., Yang Z.-C., Wrighton S.A., Jacob P., Benowitz N.L. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem. Res. Toxicol. 5(5):1992;639-646.
4. Ebert R.V., McNabb M.E., McCusker K.T., Snow S.L. Amount of nicotine and carbon monoxide inhaled by smokers of low-tar, low-nicotine cigarettes. JAMA, J. Am. Med. Assoc. 250(20):1983;2840-2842.
5. First M.B., Spitzer R.L., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders. 1995;New York Psychiatric Institute, Biometrics Research Department, NY, NY 10032.
6. Fagerström K.O. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict. Behav. 3(3-4):1978;235-241.
7. Fagerström K.O., Heatherton T.F., Kozlowski L.T. Nicotine addiction and its assessment. Ear Nose Throat J. 69(11):1991;763-765.
8. Gori G.B., Lynch C.J. Analytical cigarette yields as predictors of smoke bioavailability. Regul. Toxicol. Pharmacol. 5(3):1985;314-326.
9. Gorrod J.W., Wahren J. Nicotine and Related Alkaloids: Absorption, Distribution, Metabolism and Excretion. 1993;1-299 Chapman & Hall, New York.
10. Guengerich P. Human cytochrome P450 enzymes. Ortiz de Montellano P.R. Cytochrome P450 - Structure, Mechanisms, and Biochemistry. second ed. 1995;473-535 Plenum, New York. Chapter 14.
11. Guthrie S.K., Zubieta J.-K., Ohl L., Ni L., Koeppe R.A., Minoshima S., Domino E.F. Arterial/venous nicotine concentrations following nicotine nasal spray. Eur. J. Clin. Pharmacol. 55:1999;639-643.
12. Hariharan N., Van Noord T., Greden J.F. A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. Clin. Chem. 34:1988;724-729.
13. Heatherton T.F. The Fagerström Test for Nicotine Dependence. A revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 86(9):1991;1119-1127.
14. Jacob P., Benowitz N.L. Pharmacokinetics of (S)-nicotine and metabolites in humans. Gorrod J.W., Wahren J. Nicotine and Related Alkaloids: Absorption, Distribution, Metabolism and Excretion. 1993;197-218 Chapman & Hall, New York. Chapter 10.
15. Jarvis M.J., Boreham R., Primatesta P., Feyerabend C., Bryant A. Nicotine yield from machine-smoked cigarettes and nicotine intakers in smokers: evidence from a representative population survey. J. Natl. Cancer Inst. 93:2001;134-138.
16. Kyerematen G.A., Vesell E.S. Metabolism of nicotine. Drug Metab. Rev. 23(1-2):1991;3-41.
17. Messina E.S., Tyndale R.F., Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282(3):1997;1608-1614.
18. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277(2):1996;1010-1015.
19. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24(11):1996;1212-1217.
20. Oscarson, M., 2001. CYP2A6 allele nomenclature. SwissProt GenBank OMIM GeneCards «www.imm.ki.se/CYPalleles/cyp2a6.htm».
21. Park S.B., Jacob P., Benowitz N.L., Cashman J.R. Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1′-oxide. Chem. Res. Toxicol. 6:1993;880-888.
22. Perez-Stable E.J., Herrera B., Jacob P. III, Benowitz N.L. Nicotine metabolism and intake in black and white smokers. JAMA, J. Am. Med. Assoc. 280(2):1998;152-156.
23. Pianezza, M., Sellers, E.M., Tyndale, R.F., 1998a. Carriers of Defective CYP2A6 Alleles have a Decreased Risk for Tobacco Dependence and Smoke Fewer Cigarettes. #B024, Abstracts, Society for Nicotine and Tobacco Research, New Orleans, LA.
24. Pianezza M.L., Sellers E.M., Tyndale R.F. Genetically variable CYP2A6 influences smoking behaviour. Clin. Pharmacol. Ther. 63:1998;171.
25. Pianezza M.L., Sellers E.M., Tyndale R.F. Nicotine metabolism defect reduces smoking. Nature. 393(6687):1998;750.
26. Pomerleau C.S., Carton S.M., Lutzke M.L., Flessland K.A., Pomerleau O.F. Reliability of the Fagerström Tolerance Questionnaire and the Fagerström Test for Nicotine Dependence. Addict. Behav. 19(1):1994;33-39.
27. Rosa M., Pacifici R., Altieri I., Pichini S., Ottaviani G., Zuccaro P. How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine content. Clin. Pharmacol. Ther. 52:1992;324-329.
28. Russell M.A.H. Nicotine intake and its control over smoking. Wonnacott S., Russell M.A.H., Stolerman I.P. Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural Aspects. 1990;374-418 Oxford Univ. Press, Oxford. Chapter 11.
29. Russell M.A.H., Jarvis M.J., Feyerabend C., Saloojee Y. Reduction of tar, nicotine and carbon monoxide intake in low tar smokers. J. Epidemiol. Community Health. 40(1):1986;80-85.
30. Satariona W.A., Swanson G.M. Racial differences in cancer incidence: the significance of age-specific patterns. Cancer. 62(12):1998;2640-2653.
31. Sellers E.M. Pharmacogenetics and ethnoracial differences in smoking. JAMA, J. Am. Med. Assoc. 280(2):1998;179-180.
32. Sellers E.M., Tyndale R.F. Mimicking gene defects to treat drug dependence. Ann. N. Y. Acad. Sci. 909:1999;233-246.
33. Sellers E.M., Kaplan H.L., Romach M.K., Tyndale R.R. Inhibition of CYP2A6 decreases smoking. Am. Soc. Clin. Pharmacol. Ther. 65:1998;153.
34. Sellers E.M., Kaplan H.L., Tyndale R.F. Inhibition of cytochrome P4502A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68(1):2000;35-43.
35. Tyndale R.F., Li Y., Kaplan H.C., Sellers E.M. Inhibition of nicotine's metabolism. A potential new treatment for tobacco dependence. Clin. Pharmacol. 65:1999;154.
36. Tyndale R.F., Rao Y., Bodin L., Zia M., Zeman M., Hoffmann E., Sellers E.M. CYP2A6 gene defects and duplications alter objective indices of smoking. Clin. Pharmacol. Ther. 67:2000;113.
37. Wagenknecht L.E., Cutter G.R., Haley N.J., Sidney S., Manolio T.A., Hughes G.H., Jacobs D.R. Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. Am. J. Public Health. 80(9):1990;1053-1056.
38. World Health Organization, 1997. Tobacco or Health: a Global Status Report, Geneva, Switzerland.
39. Zeman, M.V., Pianezza, M.L., Li, N.-Y., Tyndale, R.F., Sellers, E.M., 1998a. In vivo measurement of variations in cytochrome P-4502A6 (CYP2A6) activity. #CO13, Society for Research on Nicotine and Tobacco Meeting, New Orleans, LA.
40. Zeman M.V., Pianezza M.L., Li N.-Y., Tyndale R.F., Sellers E.M. Characterization of CYP2A6 activity using plasma coumarin measurements. Clin. Pharmacol. Ther. 63:1998;215.